AI Generated Image
Experimental Cancer Drug Force-Feeds Tumors Sugar Until They Choke
Yahoo • • health
Key Points:
- Researchers at the University of Washington and UT Austin have developed XJ-4-85, an experimental compound that uniquely activates rather than starves cancer metabolism by overdriving the enzyme PFKL and blocking fat metabolism via CPT2 inhibition.
- XJ-4-85 is a precise "electrophile-drug conjugate" that selectively targets a single lysine on PFKL and CPT2 protein sites, demonstrating high specificity in both human and mouse cells.
- In mouse melanoma models, XJ-4-85 significantly reduced tumor size over two weeks with minimal side effects, and its efficacy depends largely on PFKL activation, as shown by genetic knockout experiments.
- Despite promising preclinical results, no human trials have been conducted, and concerns remain about potential long-term toxicity given PFKL and CPT2's roles in healthy tissues like heart and muscle.
- This research challenges traditional cancer treatment strategies focused on glucose starvation by proposing a novel approach that simultaneously accelerates glycolysis and blocks fat metabolism, warranting further investigation in oncology.
